Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

476.10INR
16 Aug 2019
Change (% chg)

Rs-2.20 (-0.46%)
Prev Close
Rs478.30
Open
Rs477.00
Day's High
Rs483.40
Day's Low
Rs474.50
Volume
1,279,325
Avg. Vol
2,107,610
52-wk High
Rs678.45
52-wk Low
Rs465.00

Latest Key Developments (Source: Significant Developments)

Cipla To Buy Stake Of Eight Roads Investment Mauritius II In Unit Cipla Health
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Cipla Ltd ::SIGNED DEFINITIVE DEAL TO BUY MINORITY STAKE OF EIGHT ROADS INVESTMENT MAURITIUS II IN UNIT CIPLA HEALTH.DEAL FOR 3.50 BILLION RUPEES.  Full Article

India's Cipla June Qtr Consol Net Profit Attributable Rises
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Cipla Ltd ::JUNE QUARTER CONSOL NET PROFIT ATTRIBUTABLE 4.78 BILLION RUPEES VERSUS 4.51 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR JUNE QUARTER CONSOL NET PROFIT WAS 4.96 BILLION RUPEES.JUNE QUARTER CONSOL NET SALES 38.94 BILLION RUPEES VERSUS 38.46 BILLION RUPEES LAST YEAR.  Full Article

FDA Approves First Generics Of Lyrica
Monday, 22 Jul 2019 

July 22 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES FIRST GENERICS OF LYRICA.U.S. FOOD AND DRUG ADMINISTRATION SAYS ON JULY 19, FDA APPROVED MULTIPLE APPLICATIONS FOR FIRST GENERICS OF LYRICA (PREGABALIN).U.S. FDA SAYS GRANTED APPROVALS FOR GENERIC VERSIONS OF LYRICA TO ALKEM LABORATORIES, DR. REDDY'S LABORATORIES, INVAGEN PHARMACEUTICALS.U.S. FDA SAYS ALSO GRANTED APPROVALS FOR GENERIC VERSIONS OF LYRICA TO MSN LABORATORIES LTD, SCIEGEN PHARMACEUTICALS INC, AND TEVA PHARMACEUTICALS.  Full Article

Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC
Monday, 1 Apr 2019 

April 1 (Reuters) - Cipla Ltd ::PULMATRIX ENTERS INTO BINDING TERM SHEET WITH CIPLA TECHNOLOGIES LLC FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PULMAZOLE.PULMATRIX - BINDING TERM SHEET EXECUTED ON APRIL 1, 2019 LAYS GROUNDWORK FOR ENTRY INTO A DEFINITIVE AGREEMENT DURING 2ND QUARTER OF 2019.PULMATRIX - CIP TEC TO MAKE AN UPFRONT PAYMENT OF $22 MILLION TO CO IN EXCHANGE FOR ASSIGNMENT OF ALL RIGHTS TO PULMAZOLE TO CIP TEC.PULMATRIX - ENTRY INTO DEFINITIVE AGREEMENT IS CONTINGENT UPON, CO HAVING AT LEAST $15 MILLION IN UNENCUMBERED FUNDS.PULMATRIX INC - PULMATRIX TO RETAIN RIGHT TO RECEIVE 50% OF FREE CASH FLOW FROM FUTURE SALES OF PULMAZOLE.PULMATRIX INC - CO TO REMAIN PRIMARILY RESPONSIBLE FOR IMPLEMENTATION OF CLINICAL DEVELOPMENT OF PULMAZOLE.PULMATRIX INC - CIP TEC WILL BE RESPONSIBLE FOR IMPLEMENTATION OF COMMERCIALIZATION OF PULMAZOLE.  Full Article

Cipla, Unit Cipla USA Announce Phased Launch Of Generic Cinacalcet Hydrochloride Tablets In USA
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Cipla Ltd ::CO, UNIT CIPLA USA ANNOUNCED A PHASED LAUNCH OF GENERIC CINACALCET HYDROCHLORIDE TABLETS IN USA.SAYS "LAUNCH IS A SUBJECT OF ONGOING LITIGATION".  Full Article

Cipla Says Co, Wellthy Therapeutics Enter Partnership
Monday, 18 Feb 2019 

Feb 18 (Reuters) - Cipla Ltd ::CO & WELLTHY THERAPEUTICS ENTER PARTNERSHIP TO OFFER COMBINATION OF PHARMACOTHERAPY & DIGITAL THERAPEUTICS OF DIABETOLOGY & CARDIOLOGY.DEAL WORTH CASH CONSIDERATION OF 105 MILLION RUPEES.  Full Article

Cipla Gets Final Nod For Generic Version Of Eli Lilly & Co.'s Adcirca
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Cipla Ltd ::SAYS RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ELI LILLY & CO.'S ADCIRCA.SAYS PRODUCT IS AVAILABLE FOR SHIPPING IMMEDIATELY.  Full Article

India's Cipla Dec-Qtr Consol Profit Falls Over 17 Pct
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Cipla Ltd ::DEC QUARTER CONSOL NET PROFIT 3.32 BILLION RUPEES VERSUS 4.01 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 3.72 BILLION RUPEES.DEC QUARTER CONSOL NET SALES 39.06 BILLION RUPEES VERSUS 38.34 BILLION RUPEES LAST YEAR.SAYS DEC-QUARTER TOTAL TAX EXPENSE 1.26 BILLION RUPEES.  Full Article

Cipla Gets USFDA Final Approval For Generic Version Of Depo-Provera
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Cipla Ltd ::GETS FINAL APPROVAL FOR GENERIC VERSION OF PFIZER’S DEPO-PROVERA® (MEDROXYPROGESTERONE INJECTABLE, 150MG/ML ).  Full Article

Cipla Gets Final Approval For Generic Version Of Roche's Valcyte
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Cipla Ltd ::CIPLA RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ROCHE'S VALCYTE (VALGANCICLOVIR TABLETS 450MG).  Full Article

BUZZ-India's Cipla rises after U.S. FDA closes inspection at Goa unit

** Shares of generic drugmaker Cipla Ltd rise as much as 3.41 pct to 538.75 rupees, their highest in a fortnight